Document is current
Any future updates will be listed below
-
Authors
Sutton, Thomas L.
Walker, Brett S.
Billingsley, Kevin G.
Corless, Christopher L.
Sheppard, Brett C.
Heinrich, Michael C.
Mayo, Skye C.
- License Information
-
More Information
Article History
Received: 15 February 2022
Accepted: 4 June 2022
First Online: 12 July 2022
Disclosure
: Michael Heinrich receives consulting fees from Novartis, Deciphera Pharmaceuticals, Blueprint Medicines, and Theseus Pharmaceuticals, and holds multiple patents on the diagnosis and/or treatment of GIST. One patent on the treatment of GIST has been licensed by OHSU to Novartis. Thomas L. Sutton, Brett S. Walker, Kevin G. Billingsley, Christopher L. Corless, Brett C. Sheppard, and Skye C. Mayo have no conflicts of interest to declare.
